Harrow to Announce Third Quarter 2022 Financial Results on November 14, 2022
10/28/2022 - 08:00 AM
NASHVILLE --(BUSINESS WIRE)--
Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced that it will release its financial results for the third quarter ended September 30, 2022 , on Monday, November 14, 2022 , after the market close. The Company will also post its third quarter Letter to Stockholders to the “Investors” section of its website, harrowinc.com . Harrow will host a conference call and live webcast at 4:45 p.m. Eastern Time to discuss the results and provide a business update.
Conference Call Details:
Date:
Monday, November 14, 2022
Time:
4:45 p.m. Eastern time
Participant Dial -in:
1-833-953-2434 (U.S. )
Replay Dial -in (Passcode 7735845):
(telephonic replay through November 21, 2022 )
1-877-344-7529 (U.S. )
Webcast: (online replay through February 14, 2023 )
harrowinc.com
About Harrow
Harrow (Nasdaq: HROW) is an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies that are accessible and affordable. For more information about Harrow, including investor-related materials, please visit the corporate website, harrowinc.com , or Harrow’s LinkedIn page.
View source version on businesswire.com : https://www.businesswire.com/news/home/20221027005179/en/
Jamie Webb , Director of Communications and Investor Relations
jwebb@harrowinc.com
Source: Harrow
HROW Rankings
#1113 Ranked by Stock Gains
HROW Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Other, Pharmaceuticals: Major, Manufacturing, Pharmaceutical Preparation Manufacturing
About HROW
harrow health, inc., together with its subsidiaries, develops, produces, and sells medications for unmet needs primarily in the united states. the company primarily provides ophthalmology based formulations to physicians and patients; and sterile and non-sterile compounded medications. it also develops and commercializes therapeutics for treating ocular surface diseases; and non-intravenous sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. its products portfolio includes topical eye drop drug candidates, including surf-100 and surf-200; surf-300, an oral capsule for treating patients suffering from ocular surface diseases, and ded signs and symptoms; klarity drops to protect and rehabilitate the ocular surface pathology for patients with ded; melt-100, a drug that is administered sublingually for conscious sedation during cataract surgery; may-66 that is used for the treatment of symptoms associated with peyronie's diseas
